- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00048958
급성 백혈병 및 다발성 골수종의 세포 유전학 연구
2024년 7월 30일 업데이트: Alliance for Clinical Trials in Oncology
급성 백혈병 및 다발성 골수종에 대한 세포 유전학 연구: 이전에 치료받지 않은 급성 골수성 백혈병(AML), 급성 림프구성 백혈병(ALL), 골수이형성 증후군(MDS) 또는 다발성 골수종(MM) 환자에 대한 CALGB 치료 연구와 병행
이전에 AML, ALL, MDS 또는 MM으로 치료받지 않은 환자의 염색체 분석 또는 유전적 차이 연구는 질병의 진단 및 분류에 도움이 될 수 있습니다.
또한 질병 경과를 예측하고 치료법을 선택하는 능력을 향상시킬 수 있습니다.
기관은 CALGB 8461에 환자를 등록하기 위해 Alliance에서 승인한 세포유전학자 또는 Alliance에서 승인한 주요 회원 세포유전학 실험실의 동의를 받아야 합니다.
Alliance Approved Institutional Cytogeneticists 목록은 Alliance for Clinical Trials in Oncology 웹사이트에 게시됩니다.
연구 개요
연구 유형
관찰
등록 (추정된)
9000
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
California
-
La Jolla, California, 미국, 92093-0658
- Rebecca and John Moores UCSD Cancer Center
-
Mountain View, California, 미국, 94040
- Camino Medical Group - Treatment Center
-
San Diego, California, 미국, 92134
- Naval Medical Center - San Diego
-
San Diego, California, 미국, 92108
- Kaiser Permanente Medical Office -Vandever Medical Office
-
San Francisco, California, 미국, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Delaware
-
Lewes, Delaware, 미국, 19958
- Tunnell Cancer Center at Beebe Medical Center
-
Newark, Delaware, 미국, 19713
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, 미국, 20007
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
-
Washington, District of Columbia, 미국, 20010
- Washington Cancer Institute at Washington Hospital Center
-
-
Florida
-
Fort Lauderdale, Florida, 미국, 33308
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
-
Jupiter, Florida, 미국, 33458
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center
-
Miami Beach, Florida, 미국, 33140
- CCOP - Mount Sinai Medical Center
-
-
Illinois
-
Bloomington, Illinois, 미국, 61701
- Illinois CancerCare - Bloomington
-
Bloomington, Illinois, 미국, 61701
- St. Joseph Medical Center
-
Canton, Illinois, 미국, 61520
- Illinois CancerCare - Canton
-
Canton, Illinois, 미국, 61520
- Graham Hospital
-
Carthage, Illinois, 미국, 62321
- Memorial Hospital
-
Carthage, Illinois, 미국, 62321
- Illinois CancerCare - Carthage
-
Chicago, Illinois, 미국, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, 미국, 60612-7243
- University of Illinois Cancer Center
-
Eureka, Illinois, 미국, 61530
- Illinois CancerCare - Eureka
-
Eureka, Illinois, 미국, 61530
- Eureka Community Hospital
-
Evanston, Illinois, 미국, 60201-1781
- Evanston Hospital
-
Galesburg, Illinois, 미국, 61401
- Illinois CancerCare - Galesburg
-
Galesburg, Illinois, 미국, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, 미국, 62644
- Mason District Hospital
-
Havana, Illinois, 미국, 62644
- Illinois CancerCare - Havana
-
Kewanee, Illinois, 미국, 61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb, Illinois, 미국, 61455
- Illinois CancerCare - Macomb
-
Macomb, Illinois, 미국, 61455
- Mcdonough District Hospital
-
Monmouth, Illinois, 미국, 61462
- Illinois CancerCare - Monmouth
-
Monmouth, Illinois, 미국, 61462
- OSF Holy Family Medical Center
-
Normal, Illinois, 미국, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, 미국, 61761
- Community Cancer Center
-
Normal, Illinois, 미국, 61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa, Illinois, 미국, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, 미국, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, 미국, 61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin, Illinois, 미국, 61603
- Illinois CancerCare - Pekin
-
Peoria, Illinois, 미국, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, 미국, 61614
- Proctor Hospital
-
Peoria, Illinois, 미국, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, 미국, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, 미국, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, 미국, 61354
- Illinois CancerCare - Peru
-
Peru, Illinois, 미국, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, 미국, 61356
- Perry Memorial Hospital
-
Princeton, Illinois, 미국, 61356
- Illinois CancerCare - Princeton
-
Spring Valley, Illinois, 미국, 61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46845
- Fort Wayne Medical Oncology and Hematology
-
-
Iowa
-
Cedar Rapids, Iowa, 미국, 52402
- St. Luke's Hospital
-
Cedar Rapids, Iowa, 미국, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Cedar Rapids, Iowa, 미국, 52402
- Iowa Blood and Cancer Care
-
Iowa City, Iowa, 미국, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kansas
-
Overland Park, Kansas, 미국, 66209
- Menorah Medical Center
-
Overland Park, Kansas, 미국, 66213
- Saint Luke's Hospital - South
-
Prairie Village, Kansas, 미국, 66208
- CCOP - Kansas City
-
-
Maine
-
Augusta, Maine, 미국, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, 미국, 04401
- CancerCare of Maine at Eastern Maine Medical Center
-
Scarborough, Maine, 미국, 04074
- Maine Center for Cancer Medicine and Blood Disorders - Scarborough
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
Baltimore, Maryland, 미국, 21237
- Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
-
Elkton, Maryland, 미국, 21921
- Union Hospital of Cecil County
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02115
- Dana-Farber/Brigham and Women's Cancer Center
-
Boston, Massachusetts, 미국, 02115
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
-
-
Michigan
-
Battle Creek, Michigan, 미국, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, 미국, 49307
- Mecosta County Medical Center
-
Grand Rapids, Michigan, 미국, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, 미국, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, 미국, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Muskegon, Michigan, 미국, 49444
- Mercy General Health Partners
-
Reed City, Michigan, 미국, 49677
- Spectrum Health Reed City Hospital
-
Traverse City, Michigan, 미국, 49684
- Munson Medical Center
-
-
Minnesota
-
Duluth, Minnesota, 미국, 55805
- St. Luke's Hospital Cancer Care Center
-
Minneapolis, Minnesota, 미국, 55417
- Veterans Affairs Medical Center - Minneapolis
-
Minneapolis, Minnesota, 미국, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Missouri
-
Cape Girardeau, Missouri, 미국, 63703
- Southeast Cancer Center
-
Columbia, Missouri, 미국, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Jefferson City, Missouri, 미국, 65109
- Goldschmidt Cancer Center
-
Kansas City, Missouri, 미국, 64116
- North Kansas City Hospital
-
Kansas City, Missouri, 미국, 64132
- Research Medical Center
-
Kansas City, Missouri, 미국, 64111
- Saint Luke's Cancer Institute at Saint Luke's Hospital
-
Kansas City, Missouri, 미국, 64118
- Heartland Hematology Oncology Associates, Incorporated
-
Lee's Summit, Missouri, 미국, 64086
- Saint Luke's East - Lee's Summit
-
Liberty, Missouri, 미국, 64068
- Parvin Radiation Oncology
-
Saint Joseph, Missouri, 미국, 64506
- Heartland Regional Medical Center
-
Saint Joseph, Missouri, 미국, 64507
- Saint Joseph Oncology, Incorporated
-
Saint Louis, Missouri, 미국, 63131
- Missouri Baptist Cancer Center
-
Saint Louis, Missouri, 미국, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
Nebraska
-
Grand Island, Nebraska, 미국, 68803
- Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
-
North Platte, Nebraska, 미국, 69103
- Callahan Cancer Center at Great Plains Regional Medical Center
-
Omaha, Nebraska, 미국, 68198-6805
- UNMC Eppley Cancer Center at the University of Nebraska Medical Center
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, 미국, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, 미국, 89106
- CCOP - Nevada Cancer Research Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Voorhees, New Jersey, 미국, 08043
- Cancer Institute of New Jersey at Cooper - Voorhees
-
-
New York
-
Buffalo, New York, 미국, 14263-0001
- Roswell Park Cancer Institute
-
East Syracuse, New York, 미국, 13057
- CCOP - Hematology-Oncology Associates of Central New York
-
Glens Falls, New York, 미국, 12801
- Charles R. Wood Cancer Center at Glens Falls Hospital
-
Lake Success, New York, 미국, 11042
- Monter Cancer Center of the North Shore-LIJ Health System
-
Manhasset, New York, 미국, 11030
- CCOP - North Shore University Hospital
-
Manhasset, New York, 미국, 11030
- Don Monti Comprehensive Cancer Center at North Shore University Hospital
-
New Hyde Park, New York, 미국, 11040
- Long Island Jewish Medical Center
-
New York, New York, 미국, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
New York, New York, 미국, 10029
- Mount Sinai Medical Center
-
Syracuse, New York, 미국, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
- Mission Hospitals - Memorial Campus
-
Chapel Hill, North Carolina, 미국, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Charlotte, North Carolina, 미국, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
Concord, North Carolina, 미국, 28025
- Batte Cancer Center at Northeast Medical Center
-
Durham, North Carolina, 미국, 27710
- Duke Cancer Institute
-
Goldsboro, North Carolina, 미국, 27534
- Wayne Memorial Hospital, Incorporated
-
Greenville, North Carolina, 미국, 27834
- Leo W. Jenkins Cancer Center at ECU Medical School
-
Hendersonville, North Carolina, 미국, 28791
- Pardee Memorial Hospital
-
Kinston, North Carolina, 미국, 28501
- Kinston Medical Specialists
-
Winston-Salem, North Carolina, 미국, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
Winston-Salem, North Carolina, 미국, 27103
- Forsyth Regional Cancer Center at Forsyth Medical Center
-
-
Ohio
-
Columbus, Ohio, 미국, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- Oklahoma University Cancer Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15224-1791
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02906
- Miriam Hospital
-
Providence, Rhode Island, 미국, 02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
South Carolina
-
Florence, South Carolina, 미국, 29501
- McLeod Regional Medical Center
-
Greenville, South Carolina, 미국, 29615
- CCOP - Greenville
-
Greenville, South Carolina, 미국, 29605
- Greenville Hospital Cancer Center
-
Greenville, South Carolina, 미국, 29615
- Cancer Centers of the Carolinas - Eastside
-
Greenville, South Carolina, 미국, 29605
- Cancer Centers of the Carolinas - Faris Road
-
Greenville, South Carolina, 미국, 29605
- Cancer Centers of the Carolinas - Grove Commons
-
Greer, South Carolina, 미국, 29650
- Cancer Centers of the Carolinas - Greer Medical Oncology
-
Seneca, South Carolina, 미국, 29672
- Cancer Centers of the Carolinas - Seneca
-
Spartanburg, South Carolina, 미국, 29307
- Cancer Centers of the Carolinas - Spartanburg
-
-
Vermont
-
Berlin, Vermont, 미국, 05602
- Mountainview Medical
-
Burlington, Vermont, 미국, 05401
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Danville, Virginia, 미국, 24541
- Danville Regional Medical Center
-
Richmond, Virginia, 미국, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
비확률 샘플
연구 인구
학술 기관, 병원 및 진료소를 포함한 임상 종양학 연구 커뮤니티의 환자 인구.
설명
- 주 구성원 세포유전학 검사실이 해당 부속물의 샘플을 처리하는 데 동의한 경우 부속물의 환자가 자격이 있습니다.
- CALGB 8461 등록 후 1개월 이내에 이전에 치료받지 않은 AML, ALL, MDS 또는 MM 환자를 위한 CALGB 치료 연구에 등록하십시오.
- CALGB 8461 등록과 동시에 미국 내 환자를 CALGB 9665(LTB)에 등록합니다.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
치료 없음
이전에 치료를 받지 않은 AML, ALL, MDS 또는 MM 환자에 대해 프로토콜에 정의된 대로 샘플을 분석을 위해 제출하고 환자는 1개월 이내에 CALGB 치료 연구에 등록해야 합니다.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
성인 AML, ALL, MDS 및 MM에서 덜 흔한 특정 1차 및 일반적인 2차 염색체 이상 발생률 확인
기간: 최대 10년
|
최대 10년
|
|
특정(정상 또는 다양한 1차 및 2차 염색체 이상)과 임상 및 실험실 매개변수의 상관 관계를 확인합니다.
기간: 최대 10년
|
최대 10년
|
|
다양한 유도 및 유도 후 요법으로 치료받은 환자의 반응률, 반응 기간, 생존 및 치료와 특정 핵형 그룹의 상관 관계
기간: 최대 10년
|
최대 10년
|
|
CALGB 백혈병 프로토콜에서 연구된 바와 같이 특정 핵형 그룹을 선택된 분자 이상과 연관시킵니다.
기간: 최대 10년
|
최대 10년
|
|
특정 핵형 그룹을 다제 내성 데이터와 연관시키기 위해
기간: 최대 10년
|
최대 10년
|
|
특정 핵형 그룹을 역학 데이터(독성 노출 및 가족력)와 연관시키기 위해
기간: 최대 10년
|
최대 10년
|
|
재발 시 핵형 변화 및 후속 임상 과정에서 재발 시 핵형 변화 유형(또는 변화 없음)의 영향을 확인하기 위해
기간: 최대 10년
|
최대 10년
|
|
백혈병 발생에 중요한 새로운 염색체 이상을 확인하기 위해
기간: 최대 10년
|
최대 10년
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 연구 의자: Clara Bloomfield, MD, James Cancer Hospital and Solove Research Institute
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Walker CJ, Kohlschmidt J, Eisfeld AK, Mrozek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2.
- Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mromicronzek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, Burd A, Levine RL, Druker BJ, Bloomfield CD, Byrd JC. A precision medicine classification for treatment of acute myeloid leukemia in older patients. J Hematol Oncol. 2021 Jun 23;14(1):96. doi: 10.1186/s13045-021-01110-5.
- Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM; Cancer and Leukemia Group B. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 1;103(11):4036-42. doi: 10.1182/blood-2003-09-3118. Epub 2004 Feb 19.
- Fobare S, Kohlschmidt J, Ozer HG, Mrozek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022 Mar 8;6(5):1371-1380. doi: 10.1182/bloodadvances.2021006242.
- Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20;23(24):5705-17. doi: 10.1200/JCO.2005.15.610.
- Mrozek K, Carroll AJ, Maharry K, et al.: Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: The Cancer and Leukemia Group B (CALGB) 8461 experience. [Abstract] Blood 104 (11): A-1081, 2004.
- Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 1;102(5):1613-8. doi: 10.1182/blood-2003-02-0359. Epub 2003 May 15.
- Heinonen K, Rao PN, Slack JL, Cruz J, Bloomfield CD, Mrozek K. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol. 1996 Jun;93(3):677-80. doi: 10.1046/j.1365-2141.1996.d01-1687.x.
- Cancer and Leukemia Group B 8461; Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 1;108(1):63-73. doi: 10.1182/blood-2005-11-4354. Epub 2006 Mar 7.
- Farag SS, Ruppert AS, Mrozek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20;23(3):482-93. doi: 10.1200/JCO.2005.06.090. Epub 2004 Nov 8.
- Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA; Cancer and Leukemia Group B (CALGB) Study 8461. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004;83 Suppl 1:S84-5. doi: 10.1007/s00277-004-0850-2. No abstract available.
- Blum W, Mrozek K, Ruppert AS, et al.: Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461. [Abstract] J Clin Oncol 22 (Suppl 14): A-6543, 568s, 2004.
- Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15;101(6):1420-7. doi: 10.1002/cncr.20489.
- Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15;22(6):1087-94. doi: 10.1200/JCO.2004.07.012.
- Marcucci G, Mrózek, K, Ruppert AS, et al.: t(8;21) Acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: a Cancer and Leukemia Group B (CALGB) Study. [Abstract] Blood 104 (11): A-2017, 2004.
- Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15;22(12):2410-8. doi: 10.1200/JCO.2004.03.023.
- Slovak ML, Bloomfield CD, Gundacker H, et al.: Acute myeloid leukemia (AML) with t(6;9)(p23;q34) defines a very poor risk leukemia subgroup with distinguishing clinicopathological features: a United States (US) Cytogenetics Intergroup Study of 62 AML and MDS cases. [Abstract] Blood 104 (11): A-567, 2004.
- Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325-36. doi: 10.1182/blood-2002-03-0772. Epub 2002 Aug 1.
- Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov;21(5):1041-51.
- Bloomfield CD, Byrd JC, Farag SS, et al.: Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). [Abstract] Ann Hematol 80 (Suppl 2): A-37, S10, 2001.
- Farag SS, Archer KJ, Carroll AJ, et al.: Isolated trisomy (IT) is an adverse prognostic factor in patients (pts) with AML: results from Cancer and Leukemia Group B (CALGB 8461). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1124, 2001.
- Marcucci G, Archer KJ, Mrózek K, et al.: Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RFS) in acute myeloid leukemia (AML): results from CALGB 8461. [Abstract] Blood 98 (11 Pt 1): A-2421, 577a, 2001.
- Wetzler M, Dodge RK, Mrozek K, et al.: Secondary chromosome aberrations in adult acute lymphoblastic leukemia (ALL) with t(9;22) - a Cancer and Leukemia Group B (CALGB) study. [Abstract] Blood 98 (11 Pt 1): A-466, 111a, 2001.
- Wetzler M, Dodge RK, Mrózek K, et al.: Karyotype change in adult acute myeloid leukemia (AML) at first relapse - CALGB 8461. [Abstract] Blood 96 (11 Pt 1): A-3046, 706a, 2000.
- Bloomfield D: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Ann Hematol 78 (Suppl 2): A-50, S13, 1999.
- Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec;17(12):3767-75. doi: 10.1200/JCO.1999.17.12.3767.
- Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999 Jun 1;93(11):3983-93.
- Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrozek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998 Mar;12(3):317-25. doi: 10.1038/sj.leu.2400933.
- Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 Sep 15;58(18):4173-9.
- Byrd JC, Dodge R, Carroll A, et al.: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Blood 92 (10 Pt 1): A-1282, 312a, 1998.
- Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, Stamberg J, Davey FR, Schiffer CA, Bloomfield CD. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res. 1998 May;4(5):1235-41.
- Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998 Jan 1;58(1):55-9.
- Heinonen K, Mrozek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD. Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol. 1998 Jun;101(3):513-20. doi: 10.1046/j.1365-2141.1998.00714.x.
- Wetzler M, Dodge RK, Mrózek K, et al.: Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 92 (10 Pt 1): A-914, 223a, 1998.
- Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997 Feb;15(2):466-75. doi: 10.1200/JCO.1997.15.2.466.
- Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997 Dec 1;90(11):4532-8.
- Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep;14(9):2486-94. doi: 10.1200/JCO.1996.14.9.2486.
- Byrd JC, Lawrence D, Arthur DC, et al.: Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are rarely cured with chemotherapy: results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1286, 188, 1996.
- Caligiuri MA, Strout MP, Arthur DC, et al.: Rearrangement of ALL1 is a recurrent molecular defect in adult acute myeloid leukemia (AML) with normal cytogenetics that predicts a short complete remission (CR) duration. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A-1060, 1996.
- Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996 Feb 3;347(8997):295-7. doi: 10.1016/s0140-6736(96)90468-7.
- Heinonen K, Mrózek K, Lawrence D, et al.: Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome. Results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1275, 186-7, 1996.
- Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 May;15(5):1786-95. doi: 10.1200/JCO.1997.15.5.1786.
- Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrozek K, Bloomfield CD. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 Dec;101(12):1516-1523. doi: 10.3324/haematol.2016.149542. Epub 2016 Jul 28.
- Farag SS, Archer KJ, Mrózek K, et al.: Pre-treatment cytogenetics predict complete remission and long-term outcome in patients (Pts) ≥60 years with acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 104 (11): A-568, 2004.
- Mrózek K, Heinonen K, Lawrence D, et al.: t(9;11)(p22;q23) confers better prognosis than other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML): a Cancer and Leukemia Group B study. [Abstract] Cytogenet Cell Genet 77: A-P332, 136, 1997.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
1984년 6월 1일
기본 완료 (추정된)
2100년 1월 1일
연구 등록 날짜
최초 제출
2002년 11월 12일
QC 기준을 충족하는 최초 제출
2003년 1월 26일
처음 게시됨 (추정된)
2003년 1월 27일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2024년 7월 31일
QC 기준을 충족하는 마지막 업데이트 제출
2024년 7월 30일
마지막으로 확인됨
2024년 7월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CALGB-8461
- NCI-2009-00494 (레지스트리 식별자: CTRP (Clinical Trials Reporting Program))
- CDR0000256897 (레지스트리 식별자: PDQ (Physician Data Query))
- 3U24CA114725-09S1 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .